Skip to main content

Advertisement

SpringerLink
Log in

Pharmacotherapeutic Options for Weight Regain After Bariatric Surgery

  • Nutrition and Obesity (O Pickett-Blakely, Section Editor)
  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Abstract

Purpose of review

We sought to critically evaluate the recent literature published over the past 3 years on the topic of weight regain after bariatric surgery in children, adolescents, and adults, with an emphasis on clinically relevant information for pharmacologic treatment of weight regain after metabolic and bariatric surgery.

Recent findings

There are multiple pharmacotherapeutic agents available to treat obesity in children, adolescents, and adults; these agents have varying efficacy and indications for use and have been studied in a variety of clinical and research scenarios. We present an overview of these findings.

Summary

This review represents a comprehensive compilation of the recently published data on efficacy of anti-obesity pharmacotherapy in the treatment of weight regain after bariatric surgery for children, adolescents, and adults.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

Similar content being viewed by others

References and Recommended Reading

  1. Hales CM, Carrol MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017-2018. NCHS data brief. 2020;(360).

  2. Hales CM, Fryar CD, Carroll MD, Freedman DS, Ogden CL. Trends in obesity and severe obesity prevalence in US youth and adults by sex and age, 2007-2008 to 2015-2016. JAMA. 2018;319(16):1723–5.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Upadhyay J, Farr O, Perakakis N, Ghaly W, Mantzoros C. Obesity as a disease. Med Clin North Am. 102. United States: © 2017 Elsevier Inc; 2018. p. 13-33.

  4. Pedroso FE, Angriman F, Endo A, Dasenbrock H, Storino A, Castillo R, et al. Weight loss after bariatric surgery in obese adolescents: a systematic review and meta-analysis. Surg Obes Relat Dis. 14. United States: © 2017 American Society for Bariatric Surgery. Published by Elsevier Inc; 2018. p. 413-22

  5. Sjöström L, Lindroos A-K, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683–93.

    Article  PubMed  Google Scholar 

  6. Estimate of Bariatric Surgery Numbers, 2011-2018: American Society for Metabolic and Bariatric Surgery; 2018 [updated 2018-06-26. Available from: https://asmbs.org/resources/estimate-of-bariatric-surgery-numbers.

  7. Kyler KE, Bettenhausen JL, Hall M, Fraser JD, Sweeney B. Trends in volume and utilization outcomes in adolescent metabolic and bariatric surgery at children’s hospitals. J Adolesc Health. 65. United States: © 2019 Society for Adolescent Health and Medicine. Published by Elsevier Inc; 2019. p. 331-6.

  8. Kizy S, Jahansouz C, Downey MC, Hevelone N, Ikramuddin S, Leslie D. National Trends in bariatric surgery 2012-2015: demographics, procedure selection, readmissions, and cost. Obes Surg. 27. United States 2017. p. 2933-9.

  9. Pratt JSA, Browne A, Browne NT, Bruzoni M, Cohen M, Desai A, et al. ASMBS pediatric metabolic and bariatric surgery guidelines, 2018. Surg Obes Relat Dis. 2018;14(7):882–901.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Who is a Candidate for Bariatric Surgery? : American Society for Metabolic and Bariatric Surgery; 2021 [Available from: https://asmbs.org/patients/who-is-a-candidate-for-bariatric-surgery.

  11. Griggs CL, Perez NP, Goldstone RN, Kelleher CM, Chang DC, Stanford FC, et al. National trends in the use of metabolic and bariatric surgery among pediatric patients with severe obesity. JAMA Pediatr. 2018;172(12):1191–2.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Bariatric Surgery Procedures: A; 2021 [Available from: https://asmbs.org/patients/bariatric-surgery-procedures.

  13. Chang SH, Stoll CR, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg. 2014;149(3):275–87.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Meguid MM, Glade MJ, Middleton FA. Weight regain after Roux-en-Y: a significant 20% complication related to PYY. Nutrition. 24. United States 2008. p. 832-42.

  15. . Bastos EC, Barbosa EM, Soriano GM, dos Santos EA, Vasconcelos SM. Determinants of weight regain after bariatric surgery. Arq Bras Cir Dig. 2013:26–32 This study showed that while bariatric surgery promotes adequate reduction of excess body weight, significant weight regain may occur after 5 years, most often correlated with post-operative time and work activity related to eating out.

  16. •• Stanford FC, Alfaris N, Gomez G, Ricks ET, Shukla AP, Corey KE, et al. The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: a multi-center study. Surg Obes Relat Dis. 2017;13(3):491–500 This study showed weight loss pharmacotherapy is a useful adjunct to bariatric surgery in patients with inadequate weight loss or weight regain; of the 15 medications evaluated, topiramate was the only medication that demonstrated a statistically significant response for weight loss.

    Article  PubMed  Google Scholar 

  17. • Cadena-Obando D, Ramírez-Rentería C, Ferreira-Hermosillo A, Albarrán-Sanchez A, Sosa-Eroza E, Molina-Ayala M, et al. Are there really any predictive factors for a successful weight loss after bariatric surgery? BMC Endocr Disord. 2020;20(1):20 This study found that nearly 20% of patients who undergo bariatric surgery will not lose more than 50% excess body weight, and the factors influencing post-operative weight nadir are still controversial but may be population-specific.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. •• Velapati SR, Shah M, Kuchkuntla AR, Abu-Dayyeh B, Grothe K, Hurt RT, et al. Weight regain after bariatric surgery: prevalence, etiology, and treatment. Curr Nutr Rep. 2018;7:329–34 This article reviews the prevalence, etiology and treatment of post-bariatric surgery weight regain and calls for clinicians to counsel patients seeking bariatric surgery on the likelihood of weight regain as well as inform them of treatment options if weight regain occurs.

    Article  PubMed  Google Scholar 

  19. Skinner AC, Ravanbakht SN, Skelton JA, Perrin EM, Armstrong SC. Prevalence of obesity and severe obesity in US children, 1999-2016. Pediatrics. 2018;141(3).

  20. Di Cesare M, Sorić M, Bovet P, Miranda JJ, Bhutta Z, Stevens GA, et al. The epidemiological burden of obesity in childhood: a worldwide epidemic requiring urgent action. BMC Med. 2019;17(1):212.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity among adults and youth: United States, 2015-2016. NCHS Data Brief. 2017(288):1–8.

  22. Simmonds M, Llewellyn A, Owen CG, Woolacott N. Predicting adult obesity from childhood obesity: a systematic review and meta-analysis. Obes Rev. 2016;17(2):95–107.

    Article  CAS  PubMed  Google Scholar 

  23. • Styne DM, Arslanian SA, Connor EL, Farooqi IS, Murad MH, Silverstein JH, et al. Pediatric obesity-assessment, treatment, and prevention: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(3):709–57 This concensus statement reviews clinical practice guidelines for the assessment, treatment and prevention of pediatric obesity.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Novo Nordisk. FDA approves Saxenda® for the treatment of obesity in adolescents aged 12-17. Novonordisk-us.com. Published December 4, 2020. Accessed January 7, 2021. https://www.novonordisk-us.com/media/news-releases.html?123001.

  25. • Markham A. Setmelanotide: First Approval. Drugs. 2021;81(3):397–403 Setmelanotide received its first approval in the United States for chronic weight management in patients 6 years and older.

    Article  CAS  PubMed  Google Scholar 

  26. Armstrong SC, Bolling CF, Michalsky MP, Reichard KW. Section On Obesity SOS. Pediatric metabolic and bariatric surgery: evidence, barriers, and best practices. Pediatrics. 2019;144(6).

  27. Srivastava G, Fox CK, Kelly AS, Jastreboff AM, Browne AF, Browne NT, et al. Clinical considerations regarding the use of obesity pharmacotherapy in adolescents with obesity. Obesity (Silver Spring). 2019;27(2):190–204.

    Article  Google Scholar 

  28. Inge TH, Jenkins TM, Xanthakos SA, Dixon JB, Daniels SR, Zeller MH, et al. Long-term outcomes of bariatric surgery in adolescents with severe obesity (FABS-5+): a prospective follow-up analysis. Lancet Diabetes Endocrinol. 2017;5(3):165–73.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Olbers T, Beamish AJ, Gronowitz E, Flodmark CE, Dahlgren J, Bruze G, et al. Laparoscopic Roux-en-Y gastric bypass in adolescents with severe obesity (AMOS): a prospective, 5-year, Swedish nationwide study. Lancet Diabetes Endocrinol. 2017;5(3):174–83.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Inge TH, Courcoulas AP, Jenkins TM, Michalsky MP, Helmrath MA, Brandt ML, et al. Weight loss and health status 3 years after bariatric surgery in adolescents. N Engl J Med. 2016;374(2):113–23.

    Article  CAS  PubMed  Google Scholar 

  31. •• Toth AT, Gomez G, Shukla AP, Pratt JS, Cena H, Biino G, et al. Weight Loss Medications in young adults after bariatric surgery for weight regain or inadequate weight loss: a multi-center study. Children (Basel). 2018;5(9) This study found that topiramate, phentermine and metformin are promising weight loss medications for young adults aged 21 to 30 years, and those who start medication at the postsurgical nadir as opposed to after weight regain achieved greater weight loss.

  32. Campoverde Reyes KJ, Misra M, Lee H, Stanford FC. Weight loss surgery utilization in patients aged 14-25 with severe obesity among several healthcare institutions in the United States. Front Pediatr. 2018;6:251.

    Article  PubMed  PubMed Central  Google Scholar 

  33. •• Stanford FC. Controversial issues: a practical guide to the use of weight loss medications after bariatric surgery for weight regain or inadequate weight loss. Surg Obes Relat Dis. 2019;15(1):128–32 This paper provides guidance on how to initiate several anti-obesity medications after weight loss surgery in patients.

    Article  PubMed  Google Scholar 

  34. •• Nor Hanipah Z, Nasr EC, Bucak E, Schauer PR, Aminian A, Brethauer SA, et al. Efficacy of adjuvant weight loss medication after bariatric surgery. Surg Obes Relat Dis. 2018;14(1):93–8 This study showed that adjuvant weight loss medications halted weight regain in patients who experienced post-bariatric surgical weight regain; the effect was more significant in those who had undergone gastric bypass (compared to gastric sleeve) and those with higher body mass index.

    Article  PubMed  Google Scholar 

  35. • Sudlow AC, le Roux CW, Pournaras DJ. Review of advances in anti-obesity pharmacotherapy: implications for a multimodal treatment approach with metabolic surgery. Obes Surg. 2019;29(12):4095–104 This review provides an overview of the most recently-developed anti-obesity medications and discusses the opportunities for providing multimodal care using anti-obesity pharmacotherapy in post-bariatric surgical weight regain.

    Article  Google Scholar 

  36. Grandone A, Di Sessa A, Umano GR, Toraldo R, Miraglia Del Giudice E. New treatment modalities for obesity. Best Pract Res Clin Endocrinol Metab. 2018;32(4):535–49.

    Article  CAS  PubMed  Google Scholar 

  37. Lockie SH, Heppner KM, Chaudhary N, Chabenne JR, Morgan DA, Veyrat-Durebex C, et al. Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling. Diabetes. 2012;61(11):2753–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A Randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22.

    Article  PubMed  CAS  Google Scholar 

  39. • Suliman M, Buckley A, Al Tikriti A, Tan T, le Roux CW, Lessan N, et al. Routine clinical use of liraglutide 3 mg for the treatment of obesity: outcomes in non-surgical and bariatric surgery patients. Diabetes Obes Metab. 2019;21(6):1498–501 This study demonstrated a median weight loss of 6.4% in patients treated with liraglutide, and no significant difference in weight loss between those who had prior bariatric surgery vs those who had not.

    Article  CAS  PubMed  Google Scholar 

  40. •• Gazda CL, Clark JD, Lingvay I, Almandoz JP. Pharmacotherapies for post-bariatric weight regain: real-world comparative outcomes. Obesity (Silver Spring). 2021; This study found that GLP-1 receptor agonist medications were found to be more effective for treating post-bariatric weight regain than non-GLP-1 receptor agonist medications or intensive lifestyle modification, regardless of surgery type.

  41. •• Wharton S, Kuk JL, Luszczynski M, Kamran E, RAG C. Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery. Clin Obes. 2019;9(4):e12323 This study found that post-bariatric surgery patients can lose a significant amount of weight while taking liraglutide 3.0 mg regardless of the type of surgery they had; like non-surgical populations, post-bariatric surgery patients taking liraglutide 3.0 mg may experience gastrointestinal side effects such as nausea, and can continue to lose weight up to 1 year.

    Article  PubMed  PubMed Central  Google Scholar 

  42. •• Rye P, Modi R, Cawsey S, Sharma AM. Efficacy of high-dose liraglutide as an adjunct for weight loss in patients with prior bariatric surgery. Obes Surg. 2018;28(11):3553–8 This study found high-dose liraglutide to be an effective adjunct treatment for weight loss in patients with prior bariatric surgery, showing 16-week median weight loss of 7.1% and 28-week median weight loss of 9.7% body weight.

    Article  PubMed  Google Scholar 

  43. Enebo LB, Berthelsen KK, Kankam M, Lund MT, Rubino DM, Satylganova A, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021.

  44. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989.

    Article  CAS  PubMed  Google Scholar 

  45. Frias JP, Nauck MA, Van J, Benson C, Bray R, Cui X, et al. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes Obes Metab. 2020;22(6):938–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. •• Srivastava G, Buffington C. A specialized medical management program to address post-operative weight regain in bariatric patients. Obes Surg. 2018;28(8):2241–6 This study concluded that a medically supervised weight management program complementary to surgery is beneficial for the treatment of weight regain and is important in assisting the surgical patient in achieving long-term weight loss success.

    Article  PubMed  Google Scholar 

  47. •• Stanford FC, Toth AT, Shukla AP, Pratt JS, Cena H, Biino G, et al. Weight loss medications in older adults after bariatric surgery for weight regain or inadequate weight loss: a multicenter study. Bariatr Surg Pract Patient Care. 2018;13(4):171–8 This study found that weight loss medications are a useful treatment to confer additional weight loss in adults 60 years of age and older after Roux-en-Y gastric bypass and sleeve gastrectomy.

    Article  PubMed  PubMed Central  Google Scholar 

  48. •• Gutt S, Schraier S, Gonzalez Bagnes MF, Yu M, Gonzalez CD, Di Girolamo G. Long-term pharmacotherapy of obesity in patients that have undergone bariatric surgery: pharmacological prevention and management of body weight regain. Expert Opin Pharmacother. 2019;20(8):939–47 This review summarizes the available evidence concerning long-term pharmacotherapy of obesity in patients who have undergone bariatric surgery, finding that initiation of medications at the weight plateau results in higher cumulative total weight loss, and emphasizing the beneficial effects of using pharmacotherapy to prevent and manage post bariatric surgery weight regain.

    Article  CAS  PubMed  Google Scholar 

  49. Maahs D, de Serna DG, Kolotkin RL, Ralston S, Sandate J, Qualls C, et al. Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr Pract. 2006;12(1):18–28.

    Article  PubMed  Google Scholar 

  50. Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity (Silver Spring). 2013;21(11):2163–71.

    Article  CAS  Google Scholar 

  51. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–61.

    Article  CAS  PubMed  Google Scholar 

  52. Ryder JR, Kaizer A, Rudser KD, Gross A, Kelly AS, Fox CK. Effect of phentermine on weight reduction in a pediatric weight management clinic. Int J Obes. 2017;41(1):90–3.

    Article  CAS  Google Scholar 

  53. Srivastava G, Apovian CM. Current pharmacotherapy for obesity. Nat Rev Endocrinol. 2018;14(1):12–24.

    Article  CAS  PubMed  Google Scholar 

  54. Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20(2):330–42.

    Article  CAS  Google Scholar 

  55. Cosentino G, Conrad AO, Uwaifo GI. Phentermine and topiramate for the management of obesity: a review. Drug Des Devel Ther. 2013;7:267–78.

    CAS  PubMed  Google Scholar 

  56. Kelly AS, Auerbach P, Barrientos-Perez M, Gies I, Hale PM, Marcus C, et al. A Randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382(22):2117–28.

    Article  CAS  PubMed  Google Scholar 

  57. Collet TH, Dubern B, Mokrosinski J, Connors H, Keogh JM. Mendes de Oliveira E, et al. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency. Mol Metab. 2017;6(10):1321–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Clément K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020;8(12):960–70.

    Article  PubMed  Google Scholar 

  59. de Silva VA, Suraweera C, Ratnatunga SS, Dayabandara M, Wanniarachchi N, Hanwella R. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry. 2016;16(1):341.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  60. Anagnostou E, Aman MG, Handen BL, Sanders KB, Shui A, Hollway JA, et al. Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autism spectrum disorder: a randomized clinical trial. JAMA Psychiatry. 2016;73(9):928–37.

    Article  PubMed  Google Scholar 

  61. Björkhem-Bergman L, Asplund AB, Lindh JD. Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis. J Psychopharmacol. 2011;25(3):299–305.

    Article  PubMed  Google Scholar 

  62. O'Connor EA, Evans CV, Burda BU, Walsh ES, Eder M, Lozano P. Screening for obesity and intervention for weight management in children and adolescents: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2017;317(23):2427–44.

    Article  PubMed  Google Scholar 

  63. Pilitsi E, Farr OM, Polyzos SA, Perakakis N, Nolen-Doerr E, Papathanasiou AE, et al. Pharmacotherapy of obesity: Available medications and drugs under investigation. Metabolism. 2019;92:170–92.

    Article  CAS  PubMed  Google Scholar 

  64. Seifarth C, Schehler B, Schneider HJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes. 2013;121(1):27–31.

    CAS  PubMed  Google Scholar 

  65. Takeoka M, Riviello JJ, Pfeifer H, Thiele EA. Concomitant treatment with topiramate and ketogenic diet in pediatric epilepsy. Epilepsia. 2002;43(9):1072–5.

    Article  CAS  PubMed  Google Scholar 

  66. Fox CK, Kaizer AM, Rudser KD, Nathan BM, Gross AC, Sunni M, et al. Meal replacements followed by topiramate for the treatment of adolescent severe obesity: a pilot randomized controlled trial. Obesity (Silver Spring). 2016;24(12):2553–61.

    Article  CAS  Google Scholar 

  67. Fox CK, Marlatt KL, Rudser KD, Kelly AS. Topiramate for weight reduction in adolescents with severe obesity. Clin Pediatr (Phila). 2015;54(1):19–24.

    Article  Google Scholar 

  68. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341–52.

    Article  CAS  PubMed  Google Scholar 

  69. Kramer CK, Leitão CB, Pinto LC, Canani LH, Azevedo MJ, Gross JL. Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials. Obes Rev. 2011;12(5):e338–47.

    Article  CAS  PubMed  Google Scholar 

  70. Glod CA, Lynch A, Flynn E, Berkowitz C, Baldessarini RJ. Open trial of bupropion SR in adolescent major depression. J Child Adolesc Psychiatr Nurs. 2003;16(3):123–30.

    Article  PubMed  Google Scholar 

  71. Woodard K, Louque L, Hsia DS. Medications for the treatment of obesity in adolescents. Ther Adv Endocrinol Metab. 2020;11:2042018820918789.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Kweon K, Kim HW. Effectiveness and safety of bupropion in children and adolescents with depressive disorders: a retrospective chart review. Clin Psychopharmacol Neurosci. 2019;17(4):537–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PM. Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. Obes Res. 2002;10(7):633–41.

    Article  CAS  PubMed  Google Scholar 

  74. Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O'Neil PM, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19(1):110–20.

    Article  CAS  Google Scholar 

  75. Ichikawa H, Miyajima T, Yamashita Y, Fujiwara M, Fukushi A, Saito K. Long-term study of lisdexamfetamine dimesylate in Japanese children and adolescents with attention-deficit/hyperactivity disorder. Neuropsychopharmacol Rep. 2020;40(1):52–62.

    Article  CAS  PubMed  Google Scholar 

  76. Banaschewski T, Johnson M, Nagy P, Otero IH, Soutullo CA, Yan B, et al. Growth and puberty in a 2-year open-label study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. CNS Drugs. 2018;32(5):455–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. McElroy SL, Hudson JI, Mitchell JE, Wilfley D, Ferreira-Cornwell MC, Gao J, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2015;72(3):235–46.

    Article  PubMed  Google Scholar 

  78. •• Redmond I, Shukla A, Aronne L. Use of weight loss medications in patients after bariatric surgery. Curr Obes Rep. 2021; This study asserts that adjuvant pharmacotherapy can help treat weight regain after bariatric surgery however future studies are needed to elucidate the optimal timing for starting such medications as well as the best medications or combinations of medications for managing postoperative weight regain.

Download references

Funding

This study was funded by the NIH and Massachusetts General Hospital Executive Committee on Research (ECOR) (FCS) and the NIH National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK040561, L30 DK118710) (FCS).

Author information

Authors and Affiliations

  1. Department of Medicine-Division of Endocrinology, MGH Weight Center, Massachusetts General Hospital, 50 Staniford Street, Suite 430, Boston, MA, 02114, USA

    Chika Vera Anekwe MD, MPH, Sujatha Seetharaman MD, MPH & Wesley P. Dutton MD

  2. Harvard Medical School, Boston, MA, USA

    Chika Vera Anekwe MD, MPH & Fatima Cody Stanford MD, MPH, MPA, MBA

  3. Division of General Internal Medicine, Department of Medicine, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA

    Michael G. Knight MD, MSHP

  4. Geisinger Commonwealth School of Medicine, Scranton, USA

    Shradha M. Chhabria

  5. Harvard T.H. Chan School of Public Health, Boston, USA

    Shradha M. Chhabria

  6. Department of Medicine-Division of Endocrinology-Neuroendocrine Unit, Department of Pediatrics-Division of Endocrinology, MGH Weight Center, Massachusetts General Hospital, Boston, MA, USA

    Fatima Cody Stanford MD, MPH, MPA, MBA

Authors
  1. Chika Vera Anekwe MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael G. Knight MD, MSHP
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sujatha Seetharaman MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wesley P. Dutton MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shradha M. Chhabria
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fatima Cody Stanford MD, MPH, MPA, MBA
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chika Vera Anekwe MD, MPH.

Ethics declarations

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Conflict of Interest

Chika Vera Anekwe declares that she has no conflict of interest. Michael G. Knight declares that he has no conflict of interest. Sujatha Seetharaman declares that she has no conflict of interest. Wesley P. Dutton declares that he has no conflict of interest. Shradha M. Chhabria declares that she has no conflict of interest. Fatima Cody Stanford declares that she has no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

I affirm that none of the material in this manuscript is included in another manuscript, has been published previously, or is currently under consideration for publication elsewhere.

This article is part of the Topical Collection Nutrition and Obesity

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Anekwe, C.V., Knight, M.G., Seetharaman, S. et al. Pharmacotherapeutic Options for Weight Regain After Bariatric Surgery. Curr Treat Options Gastro 19, 524–541 (2021). https://doi.org/10.1007/s11938-021-00358-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-021-00358-7

Keywords

Search

Navigation